|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.55 BRL | +7.27% |
|
+9.69% | +203.63% |
| Apr. 18 | Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil | MT |
| Apr. 17 | Biocon Limited Signs an Exclusive Licensing and Supply Agreement with Biomm S.A | CI |
Biomm S.A. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was BRL 107.09 million compared to BRL 58.67 million a year ago. Net loss was BRL 80.26 million compared to BRL 70.77 million a year ago.
Basic loss per share from continuing operations was BRL 1.18 compared to BRL 1.16 a year ago. Diluted loss per share from continuing operations was BRL 1.18.
| 1st Jan change | Capi. | |
|---|---|---|
| +203.63% | 310M | |
| -3.14% | 102B | |
| +1.47% | 96.29B | |
| +2.13% | 22.18B | |
| -15.55% | 21.2B | |
| -9.21% | 18.31B | |
| -39.98% | 17.38B | |
| -15.66% | 16.36B | |
| +4.98% | 13.97B | |
| +33.15% | 12.17B |
BIOMM S.A. 
